Long-term use of riluzole could improve the prognosis of sporadic amyotrophic lateral sclerosis patients: a real-world cohort study in China
Objectives: To investigate the effectiveness of riluzole in a long-term follow-up of cohort with sporadic amyotrophic lateral sclerosis(ALS) in a real-world study.Methods: Patients with ALS between 2007 and 2013 were followed up every three months. Survival and tracheotomy were predefined as primary...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2016-10-01
|
| Series: | Frontiers in Aging Neuroscience |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fnagi.2016.00246/full |
| _version_ | 1819055415079469056 |
|---|---|
| author | Lu Chen Xiaolu Liu Lu Tang Nan Zhang Dongsheng Fan |
| author_facet | Lu Chen Xiaolu Liu Lu Tang Nan Zhang Dongsheng Fan |
| author_sort | Lu Chen |
| collection | DOAJ |
| description | Objectives: To investigate the effectiveness of riluzole in a long-term follow-up of cohort with sporadic amyotrophic lateral sclerosis(ALS) in a real-world study.Methods: Patients with ALS between 2007 and 2013 were followed up every three months. Survival and tracheotomy were predefined as primary outcome measures. The cumulative defined daily dose(cDDD) of riluzole was estimated. The patients in the riluzole group were classified into 1 of 3 subgroups according to the cDDD quartiles. Survival was analyzed using Kaplan-Meier and Cox regression analysis.Results: Of the 1,540 ALS patients, 415 (26.9%) used riluzole, and the remainder did not. In the riluzole group, the age at onset was greater (p=0.016), the diagnostic delay was shorter (p<0.0005), the body mass index (BMI) was higher (p<0.0005), and the scores for both the functional rating scale (FRS) and the revised FRS (FRS-R) were higher (ps<0.0005) than those of the control group. The median cDDD of riluzole was 28 (2,800 mg). Although Kaplan-Meier analysis did not reveal a significant difference between the two groups (p=0.780), it showed that the prognosis of the beyond quartile 3 subgroup cDDD≥168 (16,800 mg) was significantly better than that of the other groups adjusted HR 0.488 (0.320-0.746), p=0.001.Conclusion: In China, older ALS patients and patients who had a higher BMI, shorter diagnostic delay, and higher FRS or FRS-R scores were more likely to use riluzole. Long-term use of riluzole was associated with a better prognosis for ALS patients, whereas short-term use had little effect on survival. |
| first_indexed | 2024-12-21T13:07:09Z |
| format | Article |
| id | doaj.art-bfe4481a880a4d5cabac38b188de9300 |
| institution | Directory Open Access Journal |
| issn | 1663-4365 |
| language | English |
| last_indexed | 2024-12-21T13:07:09Z |
| publishDate | 2016-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Aging Neuroscience |
| spelling | doaj.art-bfe4481a880a4d5cabac38b188de93002022-12-21T19:03:00ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652016-10-01810.3389/fnagi.2016.00246209984Long-term use of riluzole could improve the prognosis of sporadic amyotrophic lateral sclerosis patients: a real-world cohort study in ChinaLu Chen0Xiaolu Liu1Lu Tang2Nan Zhang3Dongsheng Fan4Peking University Third HospitalPeking University Third HospitalPeking University Third HospitalPeking University Third HospitalPeking University Third HospitalObjectives: To investigate the effectiveness of riluzole in a long-term follow-up of cohort with sporadic amyotrophic lateral sclerosis(ALS) in a real-world study.Methods: Patients with ALS between 2007 and 2013 were followed up every three months. Survival and tracheotomy were predefined as primary outcome measures. The cumulative defined daily dose(cDDD) of riluzole was estimated. The patients in the riluzole group were classified into 1 of 3 subgroups according to the cDDD quartiles. Survival was analyzed using Kaplan-Meier and Cox regression analysis.Results: Of the 1,540 ALS patients, 415 (26.9%) used riluzole, and the remainder did not. In the riluzole group, the age at onset was greater (p=0.016), the diagnostic delay was shorter (p<0.0005), the body mass index (BMI) was higher (p<0.0005), and the scores for both the functional rating scale (FRS) and the revised FRS (FRS-R) were higher (ps<0.0005) than those of the control group. The median cDDD of riluzole was 28 (2,800 mg). Although Kaplan-Meier analysis did not reveal a significant difference between the two groups (p=0.780), it showed that the prognosis of the beyond quartile 3 subgroup cDDD≥168 (16,800 mg) was significantly better than that of the other groups adjusted HR 0.488 (0.320-0.746), p=0.001.Conclusion: In China, older ALS patients and patients who had a higher BMI, shorter diagnostic delay, and higher FRS or FRS-R scores were more likely to use riluzole. Long-term use of riluzole was associated with a better prognosis for ALS patients, whereas short-term use had little effect on survival.http://journal.frontiersin.org/Journal/10.3389/fnagi.2016.00246/fullAmyotrophic Lateral SclerosisRiluzoleprognosisReal-world studyChinese cohort |
| spellingShingle | Lu Chen Xiaolu Liu Lu Tang Nan Zhang Dongsheng Fan Long-term use of riluzole could improve the prognosis of sporadic amyotrophic lateral sclerosis patients: a real-world cohort study in China Frontiers in Aging Neuroscience Amyotrophic Lateral Sclerosis Riluzole prognosis Real-world study Chinese cohort |
| title | Long-term use of riluzole could improve the prognosis of sporadic amyotrophic lateral sclerosis patients: a real-world cohort study in China |
| title_full | Long-term use of riluzole could improve the prognosis of sporadic amyotrophic lateral sclerosis patients: a real-world cohort study in China |
| title_fullStr | Long-term use of riluzole could improve the prognosis of sporadic amyotrophic lateral sclerosis patients: a real-world cohort study in China |
| title_full_unstemmed | Long-term use of riluzole could improve the prognosis of sporadic amyotrophic lateral sclerosis patients: a real-world cohort study in China |
| title_short | Long-term use of riluzole could improve the prognosis of sporadic amyotrophic lateral sclerosis patients: a real-world cohort study in China |
| title_sort | long term use of riluzole could improve the prognosis of sporadic amyotrophic lateral sclerosis patients a real world cohort study in china |
| topic | Amyotrophic Lateral Sclerosis Riluzole prognosis Real-world study Chinese cohort |
| url | http://journal.frontiersin.org/Journal/10.3389/fnagi.2016.00246/full |
| work_keys_str_mv | AT luchen longtermuseofriluzolecouldimprovetheprognosisofsporadicamyotrophiclateralsclerosispatientsarealworldcohortstudyinchina AT xiaoluliu longtermuseofriluzolecouldimprovetheprognosisofsporadicamyotrophiclateralsclerosispatientsarealworldcohortstudyinchina AT lutang longtermuseofriluzolecouldimprovetheprognosisofsporadicamyotrophiclateralsclerosispatientsarealworldcohortstudyinchina AT nanzhang longtermuseofriluzolecouldimprovetheprognosisofsporadicamyotrophiclateralsclerosispatientsarealworldcohortstudyinchina AT dongshengfan longtermuseofriluzolecouldimprovetheprognosisofsporadicamyotrophiclateralsclerosispatientsarealworldcohortstudyinchina |